Fox Run Management L.L.C. Grows Holdings in Inari Medical, Inc. (NASDAQ:NARI)

Fox Run Management L.L.C. grew its stake in Inari Medical, Inc. (NASDAQ:NARI) by 97.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 15,826 shares of the company’s stock after acquiring an additional 7,830 shares during the period. Fox Run Management L.L.C.’s holdings in Inari Medical were worth $808,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Smartleaf Asset Management LLC increased its stake in Inari Medical by 128.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock worth $33,000 after buying an additional 356 shares during the period. R Squared Ltd purchased a new stake in Inari Medical during the 4th quarter worth approximately $45,000. GAMMA Investing LLC increased its stake in Inari Medical by 66.8% during the 4th quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after buying an additional 786 shares during the period. KBC Group NV increased its stake in Inari Medical by 31.5% during the 4th quarter. KBC Group NV now owns 2,333 shares of the company’s stock worth $119,000 after buying an additional 559 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. increased its stake in Inari Medical by 44.2% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,113 shares of the company’s stock worth $128,000 after buying an additional 954 shares during the period. 90.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on NARI. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 target price (up from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Wells Fargo & Company reissued an “equal weight” rating and issued a $80.00 price objective (up from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Oppenheimer initiated coverage on shares of Inari Medical in a research report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price objective on the stock. Truist Financial increased their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Finally, Baird R W downgraded shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Inari Medical presently has a consensus rating of “Hold” and a consensus price target of $68.00.

Inari Medical Stock Performance

Shares of Inari Medical stock opened at $79.97 on Monday. The company has a fifty day simple moving average of $79.81 and a 200-day simple moving average of $60.30. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $79.99. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Insider Activity

In related news, Director William Hoffman sold 200,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the completion of the sale, the director now owns 238,987 shares in the company, valued at $14,451,543.89. This represents a 45.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.60% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.